TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 1 Study of NY-ESO-1 Overlapping Peptides With or Without Immunoadjuvants Montanide and Poly-ICLC Vaccination of Epithelial Ovarian Cancer, Fallopian Tube, or Primary Peritoneal Cancer Patients in Second or Third Remission
Brief Summary: This was a Phase 1, open-label study of repeated vaccination with NY-ESO-1 overlapping peptides (OLP4) with or without the immunoadjuvants Montanide and polyinosinic-polycytidylic acid - poly-L-lysine carboxymethylcellulose (poly-ICLC) administered every 3 weeks for a total of 5 vaccinations in subjects with epithelial ovarian, fallopian tube, or primary peritoneal cancer in second or third clinical remission. Study objectives included determination of the safety and immunogenicity following vaccination.


Options:
A: Arm Label: Non-randomized Cvac; Type: EXPERIMENTAL; Interventions: Biological: Cvac | Arm Label: Randomized Cvac; Type: EXPERIMENTAL; Interventions: Biological: Cvac | Arm Label: Observational standard of care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BIOLOGICAL; Name: Cvac; Assigned to Arm(s): Non-randomized Cvac, Randomized Cvac
B: Intervention Type: BIOLOGICAL; Name: CDX-1401 in combination with Resiquimod and/or Poly-ICLC; Assigned to Arm(s): N/A | Intervention Type: BIOLOGICAL; Name: CDX-1401; Assigned to Arm(s): N/A | Intervention Type: BIOLOGICAL; Name: Resiquimod; Assigned to Arm(s): N/A | Intervention Type: BIOLOGICAL; Name: poly-ICLC; Assigned to Arm(s): N/A
C: Arm Label: Cohort 1; Type: EXPERIMENTAL; Interventions: Biological: NY-ESO-1 OLP4 | Arm Label: Cohort 2; Type: EXPERIMENTAL; Interventions: Biological: NY-ESO-1 OLP4 + Montanide | Arm Label: Cohort 3; Type: EXPERIMENTAL; Interventions: Biological: NY-ESO-1 OLP4 + Montanide + Poly-ICLC | Intervention Type: BIOLOGICAL; Name: NY-ESO-1 OLP4; Assigned to Arm(s): Cohort 1 | Intervention Type: BIOLOGICAL; Name: NY-ESO-1 OLP4 + Montanide; Assigned to Arm(s): Cohort 2 | Intervention Type: BIOLOGICAL; Name: NY-ESO-1 OLP4 + Montanide + Poly-ICLC; Assigned to Arm(s): Cohort 3
D: Intervention Type: BIOLOGICAL; Name: anti-EpCAM x anti-CD3 (removab); Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Injection of Autologous CD34-Positive Cells for Improved Symptomatic Relief and Ischemic Wound Healing in Subjects With Moderate or High-Risk Critical Limb Ischemia
Brief Summary: The purpose of this study is to evaluate the safety and efficacy of intramuscular injections of adult stem cells in patients with Critical Limb Ischemia (CLI).


Options:
A: Arm Label: GM-CSF; Type: EXPERIMENTAL; Interventions: Drug: Granulocyte-Macrophage Stimulating Factor (GM-CSF) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Granulocyte-Macrophage Stimulating Factor (GM-CSF); Assigned to Arm(s): GM-CSF | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: BM-MNC; Type: EXPERIMENTAL; Interventions: Procedure: BM-MNC preparation | Arm Label: PB-MNC; Type: EXPERIMENTAL; Interventions: Procedure: PB-MNC preparation | Intervention Type: PROCEDURE; Name: BM-MNC preparation; Assigned to Arm(s): BM-MNC | Intervention Type: PROCEDURE; Name: PB-MNC preparation; Assigned to Arm(s): PB-MNC
C: Arm Label: Allogeneic Mesenchymal Stromal Cell; Type: EXPERIMENTAL; Interventions: Drug: Allogeneic Mesenchymal Stromal Cell | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Allogeneic Mesenchymal Stromal Cell; Assigned to Arm(s): Allogeneic Mesenchymal Stromal Cell | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Low Dose; Type: ACTIVE_COMPARATOR; Interventions: Biological: CD34-positive cells | Arm Label: High Dose; Type: ACTIVE_COMPARATOR; Interventions: Biological: CD34-positive cells | Arm Label: Saline; Type: PLACEBO_COMPARATOR; Interventions: Biological: Saline and 5% autologous plasma | Intervention Type: BIOLOGICAL; Name: CD34-positive cells; Assigned to Arm(s): Low Dose | Intervention Type: BIOLOGICAL; Name: CD34-positive cells; Assigned to Arm(s): High Dose | Intervention Type: BIOLOGICAL; Name: Saline and 5% autologous plasma; Assigned to Arm(s): Saline

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: RESOLUTE-III All-comers Trial: A Randomized Comparison of a Zotarolimus-Eluting Stent With an Everolimus-Eluting Stent for Percutaneous Coronary Intervention
Brief Summary: The RESOLUTE-III Allcomers trial is a prospective, multicenter, randomized, two-arm, international, non-inferiority, open-label study with 2300 patients at 15-20 centers. The study is a "real world, all comers" study.

Primary objective: to compare the Medtronic Endeavor-Resolute (Zotarolimus-Eluting stent) system with the Abbott XIENCE V (Everolimus-Eluting stent) system with respect to cardiac death, myocardial infarction (not clearly attributable to a non-target vessel), Target Lesion Revascularization at 1 year in a "real world" patient population.


Options:
A: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Device: Drug Eluting Stent (DES) | Arm Label: B; Type: EXPERIMENTAL; Interventions: Device: Drug Eluting Stent (DES) | Arm Label: C; Type: EXPERIMENTAL; Interventions: Device: Drug Eluting Stent (DES) | Intervention Type: DEVICE; Name: Drug Eluting Stent (DES); Assigned to Arm(s): A, B, C
B: Arm Label: 1. Resolute; Type: ACTIVE_COMPARATOR; Interventions: Device: Medtronic Endeavor Resolute | Arm Label: 2. XIENCE V; Type: ACTIVE_COMPARATOR; Interventions: Device: Abbott Xience V | Intervention Type: DEVICE; Name: Medtronic Endeavor Resolute; Assigned to Arm(s): 1. Resolute | Intervention Type: DEVICE; Name: Abbott Xience V; Assigned to Arm(s): 2. XIENCE V
C: Arm Label: Everolimus Arm; Type: EXPERIMENTAL; Interventions: Drug: Everolimus Eluting Coronary Stent System | Arm Label: non drug eluting stent Arm; Type: ACTIVE_COMPARATOR; Interventions: Device: cobalt chromium balloon expandable stent ( non drug eluting stent Arm) | Intervention Type: DRUG; Name: Everolimus Eluting Coronary Stent System; Assigned to Arm(s): Everolimus Arm | Intervention Type: DEVICE; Name: cobalt chromium balloon expandable stent ( non drug eluting stent Arm); Assigned to Arm(s): non drug eluting stent Arm
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Device: Biolimus eluted from an erodable stent coating (Biomatrix) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Device: bare-metal stent (Gazelle) | Intervention Type: DEVICE; Name: Biolimus eluted from an erodable stent coating (Biomatrix); Assigned to Arm(s): 1 | Intervention Type: DEVICE; Name: bare-metal stent (Gazelle); Assigned to Arm(s): 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Regular Exercise in Prevention of Excessive Weight Gain in Pregnancy. A Single Blind Randomized Controlled Trial
Brief Summary: Background:

Use of variable definitions of exercise and disparate results, emphasize the need of proper randomized controlled trials examining the relationship between physical activity and weight development during pregnancy. So far, only few intervention studies aiming at weight management during pregnancy have been performed (Gray-Donald et al., 2000,Olson et al., 2004,Polley et al., 2002,Kinnunen et al., 2007). Moreover, most of these interventions have focused on how gestational weight gain may be altered through individual counselling combining diet and exercise habits, rather than supervised training. Search on PubMed revealed no randomized controlled trial where the main outcome was to investigate how the effect of supervised structured exercise may reduce the proportion of women gaining more weight than optimal. The aim of the present study is to assess whether a 12-week aerobic exercise program during pregnancy can prevent excessive gestational weight gain.

Method:

This is a single blind randomized controlled trial to evaluate the effects of a structured, supervised aerobic exercise program on weight gain stabilization in primiparous pregnant women. The aim is to include 100 women. Interested women eligible for the present study will be invited to a pre-test including interview and assessments at the university. The women are examined three times during the study period. The first visit is between 12 and 24 weeks of gestation, the second at week 36-38 and the last 8-12 week after delivery. The exercise program consists of supervised exercise for 60 minutes, performed at least 2 times per week, for 12-16 weeks. Compliance with the training protocol is controlled by the instructors and registrations in the womens personal training diary


Options:
A: Intervention Type: BEHAVIORAL; Name: Supervised exercise for the prevention high weight gain; Assigned to Arm(s): N/A
B: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Exercise group; Type: EXPERIMENTAL; Interventions: Behavioral: A supervised physical exercise program | Intervention Type: BEHAVIORAL; Name: A supervised physical exercise program; Assigned to Arm(s): Exercise group
C: Arm Label: iball intervention; Type: EXPERIMENTAL; Interventions: Device: iball (mhealth application) | Arm Label: Standard Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: iball (mhealth application); Assigned to Arm(s): iball intervention
D: Arm Label: G1; Type: EXPERIMENTAL; Interventions: Procedure: Pregnants for receive the physical therapy guide | Intervention Type: PROCEDURE; Name: Pregnants for receive the physical therapy guide; Assigned to Arm(s): G1

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Regular Exercise in Prevention of Excessive Weight Gain in Pregnancy. A Single Blind Randomized Controlled Trial
Brief Summary: Background:

Use of variable definitions of exercise and disparate results, emphasize the need of proper randomized controlled trials examining the relationship between physical activity and weight development during pregnancy. So far, only few intervention studies aiming at weight management during pregnancy have been performed (Gray-Donald et al., 2000,Olson et al., 2004,Polley et al., 2002,Kinnunen et al., 2007). Moreover, most of these interventions have focused on how gestational weight gain may be altered through individual counselling combining diet and exercise habits, rather than supervised training. Search on PubMed revealed no randomized controlled trial where the main outcome was to investigate how the effect of supervised structured exercise may reduce the proportion of women gaining more weight than optimal. The aim of the present study is to assess whether a 12-week aerobic exercise program during pregnancy can prevent excessive gestational weight gain.

Method:

This is a single blind randomized controlled trial to evaluate the effects of a structured, supervised aerobic exercise program on weight gain stabilization in primiparous pregnant women. The aim is to include 100 women. Interested women eligible for the present study will be invited to a pre-test including interview and assessments at the university. The women are examined three times during the study period. The first visit is between 12 and 24 weeks of gestation, the second at week 36-38 and the last 8-12 week after delivery. The exercise program consists of supervised exercise for 60 minutes, performed at least 2 times per week, for 12-16 weeks. Compliance with the training protocol is controlled by the instructors and registrations in the womens personal training diary


Options:
A: Arm Label: exercise; Type: EXPERIMENTAL; Interventions: Behavioral: specific training program | Arm Label: control; Type: ACTIVE_COMPARATOR; Interventions: Other: standard | Intervention Type: OTHER; Name: standard; Assigned to Arm(s): control | Intervention Type: BEHAVIORAL; Name: specific training program; Assigned to Arm(s): exercise
B: Arm Label: 1 Bladder Health Class; Type: OTHER; Interventions: Behavioral: Bladder Health Class | Arm Label: 2 Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Bladder Health Class; Assigned to Arm(s): 1 Bladder Health Class
C: Arm Label: MyHealthebladder; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: MyHealtheBladder | Arm Label: VA Video Connect; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: VA Video Connect | Intervention Type: BEHAVIORAL; Name: VA Video Connect; Assigned to Arm(s): VA Video Connect | Intervention Type: BEHAVIORAL; Name: MyHealtheBladder; Assigned to Arm(s): MyHealthebladder
D: Intervention Type: BEHAVIORAL; Name: Supervised exercise for the prevention high weight gain; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Regular Exercise in Prevention of Excessive Weight Gain in Pregnancy. A Single Blind Randomized Controlled Trial
Brief Summary: Background:

Use of variable definitions of exercise and disparate results, emphasize the need of proper randomized controlled trials examining the relationship between physical activity and weight development during pregnancy. So far, only few intervention studies aiming at weight management during pregnancy have been performed (Gray-Donald et al., 2000,Olson et al., 2004,Polley et al., 2002,Kinnunen et al., 2007). Moreover, most of these interventions have focused on how gestational weight gain may be altered through individual counselling combining diet and exercise habits, rather than supervised training. Search on PubMed revealed no randomized controlled trial where the main outcome was to investigate how the effect of supervised structured exercise may reduce the proportion of women gaining more weight than optimal. The aim of the present study is to assess whether a 12-week aerobic exercise program during pregnancy can prevent excessive gestational weight gain.

Method:

This is a single blind randomized controlled trial to evaluate the effects of a structured, supervised aerobic exercise program on weight gain stabilization in primiparous pregnant women. The aim is to include 100 women. Interested women eligible for the present study will be invited to a pre-test including interview and assessments at the university. The women are examined three times during the study period. The first visit is between 12 and 24 weeks of gestation, the second at week 36-38 and the last 8-12 week after delivery. The exercise program consists of supervised exercise for 60 minutes, performed at least 2 times per week, for 12-16 weeks. Compliance with the training protocol is controlled by the instructors and registrations in the womens personal training diary


Options:
A: Arm Label: Lifestyle intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Physical Exercise / Physical Activity | Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Physical Exercise / Physical Activity; Assigned to Arm(s): Lifestyle intervention
B: Intervention Type: BEHAVIORAL; Name: Supervised exercise for the prevention high weight gain; Assigned to Arm(s): N/A
C: Arm Label: Exercise training; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Exercise; Assigned to Arm(s): Exercise training
D: Arm Label: Exercice; Type: OTHER; Interventions: Behavioral: preparation of the delivery | Arm Label: non-exercice; Type: OTHER; Interventions: Behavioral: preparation of the delivery | Intervention Type: BEHAVIORAL; Name: preparation of the delivery; Assigned to Arm(s): Exercice, non-exercice

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Study PXN110527: The Investigation of the Efficacy and Pharmacokinetics of XP13512 in Subjects With Neuropathic Pain Associated With Post-herpetic Neuralgia (PHN) Who Have Had an Inadequate Response to Gabapentin Treatment.
Brief Summary: The purpose of this study is evaluate the difference between two doses of gabapentin enacarbil (XP13512/GSK1838262), hereafter referred to as GEn, on pain associated with post-herpetic neuralgia.


Options:
A: Arm Label: gabapentin; Type: EXPERIMENTAL; Interventions: Drug: gabapentin | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Intervention Type: DRUG; Name: gabapentin; Assigned to Arm(s): gabapentin | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): placebo
B: Arm Label: GEn 1200mg/day; Type: EXPERIMENTAL; Interventions: Drug: GEn 1200mg/day | Arm Label: GEn 3600mg/day; Type: EXPERIMENTAL; Interventions: Drug: GEn 3600mg/day | Intervention Type: DRUG; Name: GEn 1200mg/day; Assigned to Arm(s): GEn 1200mg/day | Intervention Type: DRUG; Name: GEn 3600mg/day; Assigned to Arm(s): GEn 3600mg/day
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Pregabalin; Type: OTHER; Interventions: Drug: Pregabalin | Arm Label: GEn 1200mg/day; Type: EXPERIMENTAL; Interventions: Drug: GEn 1200mg/day | Arm Label: GEn 2400mg/day; Type: EXPERIMENTAL; Interventions: Drug: GEn 2400mg/day | Arm Label: GEn 3600mg/day; Type: EXPERIMENTAL; Interventions: Drug: GEn 3600mg/day | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: GEn 1200mg/day; Assigned to Arm(s): GEn 1200mg/day | Intervention Type: DRUG; Name: GEn 2400mg/day; Assigned to Arm(s): GEn 2400mg/day | Intervention Type: DRUG; Name: GEn 3600mg/day; Assigned to Arm(s): GEn 3600mg/day | Intervention Type: DRUG; Name: Pregabalin; Assigned to Arm(s): Pregabalin
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: gabapentin | Arm Label: 2; Type: SHAM_COMPARATOR; Interventions: Drug: Inert placebo | Intervention Type: DRUG; Name: gabapentin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Inert placebo; Assigned to Arm(s): 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Study PXN110527: The Investigation of the Efficacy and Pharmacokinetics of XP13512 in Subjects With Neuropathic Pain Associated With Post-herpetic Neuralgia (PHN) Who Have Had an Inadequate Response to Gabapentin Treatment.
Brief Summary: The purpose of this study is evaluate the difference between two doses of gabapentin enacarbil (XP13512/GSK1838262), hereafter referred to as GEn, on pain associated with post-herpetic neuralgia.


Options:
A: Intervention Type: DRUG; Name: Gabapentin extended-release tablets; Assigned to Arm(s): N/A
B: Arm Label: GEn 1200mg/day; Type: EXPERIMENTAL; Interventions: Drug: GEn 1200mg/day | Arm Label: GEn 3600mg/day; Type: EXPERIMENTAL; Interventions: Drug: GEn 3600mg/day | Intervention Type: DRUG; Name: GEn 1200mg/day; Assigned to Arm(s): GEn 1200mg/day | Intervention Type: DRUG; Name: GEn 3600mg/day; Assigned to Arm(s): GEn 3600mg/day
C: Arm Label: Sham-laser acupuncture; Type: SHAM_COMPARATOR; Interventions: Device: Sham-laser acupuncture | Arm Label: gabapentine; Type: ACTIVE_COMPARATOR; Interventions: Drug: gabapentine | Arm Label: Acupuncture; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Acupuncture | Intervention Type: DEVICE; Name: Sham-laser acupuncture; Assigned to Arm(s): Sham-laser acupuncture | Intervention Type: DRUG; Name: gabapentine; Assigned to Arm(s): gabapentine | Intervention Type: PROCEDURE; Name: Acupuncture; Assigned to Arm(s): Acupuncture
D: Arm Label: Placebo (0mg/day); Type: PLACEBO_COMPARATOR; Interventions: Drug: Intraspinal Gabapentin | Arm Label: Gabapentin Low (1mg/day); Type: ACTIVE_COMPARATOR; Interventions: Drug: Intraspinal Gabapentin | Arm Label: Gabapentin Medium (6mg/day); Type: ACTIVE_COMPARATOR; Interventions: Drug: Intraspinal Gabapentin | Arm Label: Gabapentin High (30mg/day); Type: ACTIVE_COMPARATOR; Interventions: Drug: Intraspinal Gabapentin | Intervention Type: DRUG; Name: Intraspinal Gabapentin; Assigned to Arm(s): Gabapentin High (30mg/day), Gabapentin Low (1mg/day), Gabapentin Medium (6mg/day), Placebo (0mg/day)

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Short-Term Study of Physiologic Dialysate Glucose Concentration in Chronic Hemodialysis Patients
Brief Summary: This study aims to show that using a glucose (sugar) concentration of 100 mg/dL in the dialysis fluid for hemodialysis is not inferior to using a concentration of 200 mg/dL with regard to the frequency and magnitude of blood glucose drops. Other parameters that will be compared between the two groups are blood pressure, heart rhythm, weight gain between dialysis treatments, and fatigue after the treatment.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Hemodialysis | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Hemodialysis | Intervention Type: PROCEDURE; Name: Hemodialysis; Assigned to Arm(s): 1, 2
B: Arm Label: Meditation Intervention Arm; Type: EXPERIMENTAL; Interventions: Other: Meditation | Arm Label: Control Group (No Meditation Exposure); Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Meditation; Assigned to Arm(s): Meditation Intervention Arm
C: Arm Label: Benson relaxation combined with music therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Benson relaxation combined with music therapy | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Benson relaxation combined with music therapy; Assigned to Arm(s): Benson relaxation combined with music therapy
D: Intervention Type: DRUG; Name: nandrolone decanoate; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: resistance exercise training; Assigned to Arm(s): N/A

Answer: A